Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

LifeStance Health (LFST) EBITDA Margin (2020 - 2025)

LifeStance Health (LFST) has disclosed EBITDA Margin for 6 consecutive years, with 3.05% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 519.0% to 3.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.61%, a 531.0% increase, with the full-year FY2025 number at 0.61%, up 531.0% from a year prior.
  • EBITDA Margin was 3.05% for Q4 2025 at LifeStance Health, up from 0.2% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3.05% in Q4 2025 to a low of 77.17% in Q4 2021.
  • A 5-year average of 19.18% and a median of 15.0% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -6606bps in 2021, then skyrocketed 5686bps in 2022.
  • LifeStance Health's EBITDA Margin stood at 77.17% in 2021, then surged by 74bps to 20.3% in 2022, then increased by 17bps to 16.76% in 2023, then soared by 87bps to 2.14% in 2024, then skyrocketed by 243bps to 3.05% in 2025.
  • Per Business Quant, the three most recent readings for LFST's EBITDA Margin are 3.05% (Q4 2025), 0.2% (Q3 2025), and 1.18% (Q2 2025).